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Abstract 
Objective To quantify UK incidence of severe ITP in pregnancy, determine current treatment 
strategies and establish maternal and neonatal morbidity and mortality associated with severe 
ITP in pregnancy. 
Design A prospective national cohort study 
Setting United Kingdom 
Population Women with severe ITP; defined as platelets <50 x 109/l in pregnancy or antenatal 
treatment of isolated low platelets. 
Methods Data collected via United Kingdom Obstetric Surveillance System (UKOSS) between 
1st June 2013–31st January 2015 from all UK Consultant led obstetric units. 
Main Outcome Measure Incidence of Severe ITP in pregnancy. 
Results The estimated incidence of severe ITP in pregnancy is 0.83 per 10,000 maternities (95% 
CI 0.68-1.00). 22 pregnant women (21%) did not receive any antenatal therapy, 85 (79%) had 
therapy. There was no difference between asymptomatic treated and untreated cohorts in severity 
of disease or outcome. Postpartum haemorrhage (51%) and severe postpartum haemorrhage 
(21%) was reported more frequently than the reported rate in the general pregnant population (5-
10%). No neonates required treatment for thrombocytopenia and there were no cases of neonatal 
intracranial bleeding. 
Conclusions Current UK management of severe ITP in pregnancy results in an exceptionally 
low morbidity and mortality for the neonate. Mothers with ITP remain at increased risk of severe 
post-partum haemorrhage and should be delivered at units that have the capacity to manage 
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severe PPH effectively. Whilst balancing risks for pregnancy of prophylactic antenatal treatment 
in asymptomatic women against observed low disease morbidity, we may be over treating 
asymptomatic patients.  
Keywords Platelets, Autoimmune Thrombocytopenia, Pregnancy 
Tweetable Abstract: UKOSS study of Severe ITP in pregnancy shows exceptionally low 
neonatal morbidity with current UK management. 
 
Introduction 
Primary autoimmune Thrombocytopenia (ITP) is a haemorrhagic disorder characterised by 
transient or persistent decrease in platelet count and, depending on the degree of 
thrombocytopenia, an increased risk of bleeding.1   It is an acquired autoimmune disease 
involving antibody- and cell-mediated destruction of platelets.2  ITP can present at any age, 
however like many other autoimmune conditions, it is commonly detected in women during 
reproductive years (20-40 years). The reported incidence of ITP during pregnancy ranges from 1 
in 1,000 to 1 in 10,000 pregnancies.3,4 Quantifying an incidence of severe ITP has been difficult 
due to the rarity of the disease, differentiating between other causes of thrombocytopenia in 
pregnancy and accepting changes over time in disease criteria for diagnosis. Gestational 
thrombocytopenia, a pregnancy specific thrombocytopenia, can be difficult to distinguish from 
ITP. Both diagnoses require exclusion of alternative causes, however GT is generally considered 
benign and platelets extremely rarely fall below 70 × 109/L, with very few cases ever described 
with platelets 40-50x109/L, 5 whereas ITP can be associated with maternal or neonatal bleeding 
risk.  
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Transplacental transfer of IgG platelet specific autoantibodies can induce neonatal 
thrombocytopenia and risk of intracranial haemorrhage (ICH) at delivery. Historically fears of 
bleeding risk have dominated management of ITP. In 1976, caesarean section was recommended 
for all ITP patients based on a reported perinatal mortality of 12% to 21%, largely resulting from 
birth trauma and ICH. 3 More recent studies have reported mortality rates of ITP mothers < 1% 
and ICH of neonates <1.5%, with only approximately 10% of neonates having platelet counts 
lower than 50 × 109/L. 6 
Although there is no direct correlation between neonatal and maternal platelet counts, we 
hypothesised that the risks of maternal and neonatal morbidity and mortality would be higher in 
women with more severe ITP, as shown by previous studies. 7 The aim of this study was to 
estimate the UK incidence of severe ITP in pregnancy, current management, and the maternal 
and fetal outcomes of these pregnancies using current treatment strategies. We planned to 
compare the two most common treatments, steroids and IVIG, to assess any difference in 
outcomes depending on treatment received. 
 
Methods 
We conducted a national cohort study using the UK Obstetric Surveillance System (UKOSS) to 
identify pregnant women with severe ITP. Data were collected on women who delivered over a 
20 month period, from 1st June 2013-31st January 2015. 
Data source and definitions 
We adopted a pragmatic definition of severe ITP in pregnancy as follows: 
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Either 
 a) any woman who had been diagnosed with thrombocytopenia with a platelet count of <50 x 
109/l at any point in her pregnancy prior to delivery where obstetric and hereditary causes for 
thrombocytopenia had been excluded (i.e. Pre-eclampsia, HELLP syndrome, acute fatty liver of 
pregnancy, known antiphospholipid antibody syndrome or other hereditary thrombocytopenias)  
or  
b) any pregnant woman diagnosed with an isolated thrombocytopenia where a clinical decision 
to treat the thrombocytopenia prior to delivery of the infant had been made.  
Women with immune thrombocytopenia secondary to systemic lupus erythematosus (SLE) 
Hepatitis C, CMV, HIV and HAART therapy or any condition where treatment of 
thrombocytopenia is focused on treatment of the causative disease were excluded from the study. 
The authors felt that the above criteria would almost certainly exclude cases of gestational 
thrombocytopenia (GT) based on the rarity of cases of GT with platelets <50 x 109/l, with only 
one case report from 6715 consecutive deliveries of gestational thrombocytopenia with platelets 
between 40-50x109/l.8  
By including only this cohort, we have targeted women considered “severe”, both clinically and 
by platelet count and excluded women most likely to have GT.   
The UKOSS methodology has been described in detail elsewhere.9 In brief, UKOSS case 
notification cards were sent to all 202 UK hospitals with consultant-led maternity units, with a 
tick box list to indicate whether they had seen any cases of severe ITP in pregnancy. These units 
cover all deliveries in the UK, since any women with medical complications would be referred to 
one of these units. Prospective collection of data occurred through monthly reporting of cases by 
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official UKOSS reporters at each site. When a clinician returned a card indicating a case, a 
condition-specific data collection form was sent for completion. If a completed data collection 
form was not returned, up to three reminders were sent. To encourage reporting during the study 
period, this study was presented twice at the annual UK Obstetric Haematology Group meeting 
and a notification was published in the British Journal of Haematology. At the end of the study 
period, some haematologists in centres known to manage specialist ITP populations were 
approached and asked to check all local cases were notified.  
Where data were missing or the response unclear, the reporting clinician was contacted. Data 
were collected on maternal demographics(including previous diagnosis of ITP, previous 
treatment for ITP received including splenectomy), maternal complications due to ITP both 
antenatally and postnatally, additional investigations as part of workup for ITP, antenatal 
management, management of labour and maternal, delivery and neonatal outcomes. 
The incidence of ITP was calculated using an appropriate denominator of all deliveries in the UK 
for the period of the study to give rates of severe ITP per 1000 maternities.  
Statistical methods 
SPSS Statistics 22 software (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, 
Version 22.0. Armonk, NY: IBM Corp.) was used for all analysis. Outcomes of pregnancy in 
women who had received antenatal treatment were compared with those who had received no 
antenatal treatment prior to labour. Non-parametric data was compared with Mann Whitney-U 
tests. For comparison of binary outcomes Chi2 or Fishers Exact tests were used. Once data were 
further subdivided into groups per treatment type comparative tests were not routinely performed 
due to small numbers and hence low statistical power. The overall outcomes are presented as 
descriptive data and simple percentages.   
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Results 
Incidence of ITP 
A total of 107 pregnancies in women with severe ITP were reported to UKOSS over the 20 
month period of data collection. Using statistics on maternities from the Office for National 
Statistics; the number of maternities for our period of study was 1,295,963. Therefore the 
estimate of incidence of severe ITP in pregnancy is 0.1 per 1000 maternities (0.083 per 1000 
maternities, 95% CI 0.068-1.00 per 10,000) or 1 in 10,000 maternities.    
Demographics 
Table I. shows the characteristics of women divided according to whether they received antenatal 
treatment for thrombocytopenia. There was no significant difference in any reported 
demographic characteristic. Having a known diagnosis of ITP prior to pregnancy (58%) did not 
appear to influence the decision to receive treatment. New presentations of ITP account for 42% 
of severe thrombocytopenia cases in pregnancy. The previous severity of those with known ITP, 
as determined crudely by the history of lowest platelet count, did not impact on the likelihood of 
receiving treatment in pregnancy.  
Antenatal Therapy for Severe ITP 
Eighty-five women (79%) were given treatment prior to labour for severe primary ITP in their 
pregnancy. Almost all women fall into one of three treatment groups, 1) steroids, 2) IVIG or 3) 
steroids plus IVIG. The majority received steroids (n=38, 45% of all women treated) and three of 
these women received additional high dose methylprednisolone (HDMP). For one pregnancy, it 
was unclear if the steroids given to the woman were for obstetric or haematological indication. In 
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this case there was a known prior diagnosis of ITP, steroids were given on the day before and 
day of term vaginal delivery with a lowest platelet count in pregnancy of 148 x 109/l and no 
symptoms of ITP reported in the antenatal period. The outcomes in this case were good for 
mother and neonate. Despite high platelet counts this case has been included due to steroid 
therapy. However, the lowest platelet count is reported here as an outlier (not shown in table V). 
17 women received IVIG only (20%) and 28 were prescribed a combination of steroids and IVIG 
(32%). Only two women received alternative therapies; one woman had Anti-D combined with 
platelet transfusion and one had a combination of steroids, IVIG, azathioprine 150mg OD, 
platelets and fresh frozen plasma (FFP). These women will be discussed as case reports in the 
text and are not included in tables comparing treatment regimens. 
Overall 37/107 women (35%) reported some symptoms of ITP in their pregnancy. 7 of these 37 
women did not receive any treatment, they reported bruising (n=4), purpura (n=2) and gingival 
bleeding (n=3).  Overall women who reported symptoms had a lower median platelet count in 
pregnancy than asymptomatic women (21 vs. 40 x 109/l; p=0.0001).  
All outcomes have been reported by treatment group (no treatment, steroids only, IVIG only, 
steroids and IVIG combined). Table S1 reports the indication or clinician’s reason for providing 
therapy. Over half (54%) were asymptomatic of ITP but received therapy to reach a target 
platelet count for delivery and 37% were treated prophylactically to prevent maternal sequelae of 
ITP based on a low platelet count. In five women, symptoms of ITP triggered treatment, with 
platelets of 5, 6, 14, 17 and 30 x 109/L. The symptoms reported ranged from epistaxis only to a 
combination of epistaxis, bruising and gingival bleeding. The woman with platelets of 14x109/l 
went on to receive azathioprine 150mg po od, platelets and FFP and is therefore not reported in 
table S1.  
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Treatment side effects were experienced by 7 out 83 treated women (8%) and were more 
commonly reported by women on a combination of IVIG and steroids, 5/28 (18%). Individual 
side effects are reported in Table S1. Only one woman reported more than one side effect.   
Labour Management  
Table 2 shows the onset of labour, mode of delivery, lowest platelets in pregnancy, platelets at 
delivery and anaesthetic choices per treatment group. The caesarean section (CS) rate in this 
cohort was high 42/107 (39%). The indications for CS are shown in Table S2. Instrumental 
deliveries were performed in 12 patients (11%). The lowest recorded cord platelet count 
following delivery using instrumental was 79x109/L and no complications were recorded. 
The reasons given for not requiring FBS are listed in Table 2.  In the majority (86%) of cases 
there was no indication for FBS. In 5 women (7%) a concern regarding low fetal platelets was 
cited as a contraindication to the test, two women had an FBS performed. 
The overall median platelet count at the time of delivery was 64 x 109/l. Untreated women had 
lower platelets at delivery (56 x 109/l), compared with treated women, but the difference is 
neither statistically nor clinically significant (p=0.331). 
Fourteen women received an epidural during labour (median platelet value was 102 x 109/l; 
range 14-152 x 109/l).  Twelve women had spinal anaesthesia for CS (median platelet value was 
93 x 109/l; range 23-154 x 109/l). In total there were six women who had a regional anaesthetic 
with platelets below 80 x 109/L: platelets of 14, 23, 36, 43, 64 and 67 x 109/l respectively.   
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Pregnancy Outcomes 
There were no cases of epidural, caesarean section wound or perineal haematoma following 
delivery. (Table 3) 
The most common definition of PPH is estimated blood loss ≥500 mL after birth. Severe 
postpartum haemorrhage (SPPH) is defined as blood loss from the genital tract of ≥1000 mL in 
the first 24 hours after the delivery.10 Using these definitions the rate of PPH in this cohort is 
56/107 (52%), the rate of SPPH is 22/107 (21%). One woman with a platelet count of 55 x 109/L 
after normal vaginal delivery who had needed multiple therapies, including azathioprine, 
required a hysterectomy for a subsequent SPPH.  The median platelet count for all women 
diagnosed with PPH was 58 x 109/L (range 12 – 148 x 109/L) which was significantly lower than 
the median value for those who did not have a PPH; 132 x 109/L (range 94 – 170 x 109/L, p value 
0.029), there was no difference between treated and untreated groups. 
There was one case of psychotic post-partum depression which is a recognized complication of 
prolonged steroid use in pregnancy.  
Neonatal Outcomes 
From 107 pregnancies of 110 fetuses (6 twins, 104 singletons), 108 babies were liveborn. There 
was one case of stillbirth thought to be unrelated to thrombocytopenia. One woman had an early 
miscarriage at less than 12 weeks of pregnancy. However, the rate of early pregnancy loss for 
women with severe ITP will be extremely underestimated; most pregnancies reported here were 
successful ongoing pregnancies identified after the pregnancy was booked during the first 
trimester. 
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Platelet counts measured at birth were available for 56 babies. The median birth platelet count 
was 193 x 109/l (range 59 – 373). Seven babies (12%) had platelet counts <100 x 109/l at birth 
(Table S3). 
Seventy seven babies had recorded platelet count in the neonatal period below 150 x 109/l, these 
are shown in Table 4. The remaining 54 (70%) did not have any reported thrombocytopenia. 
Two cases of thrombocytopenia could be attributed to concurrent neonatal sepsis.  
The additional two neonates not reported in the main tables (their mothers had alternative 
therapy with Anti D or azathioprine, platelets and FFP) were both liveborn without 
thrombocytopenia; one baby was temporarily admitted to the neonatal intensive care unit for 
treatment of jaundice. 
No babies received treatment for thrombocytopenia and there were no cases of intracranial 
hemorrhage or neonatal deaths. Sixteen infants (70%) were reported to have spontaneous 
recovery of their platelets. For the remaining seven infants spontaneous recovery of the platelets 
was not documented but the neonates were all discharged from hospital without treatment for 
thrombocytopenia.  
Discussion 
Main Findings  
In summary, our data suggest that the overall incidence of severe ITP in pregnancy is 0.83 in 
10,000 maternities in the UK (95% CI 0.68-1.00). Severe ITP in pregnancy carries a high risk for 
severe postpartum haemorrhage and outcomes for neonates were better than expected with no 
cases of intracranial haemorrhage or death.   
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There is variation in treatment of severe ITP in pregnancy among clinicians in the UK at present. 
This allowed us to directly compare outcomes of patients who did not receive antenatal treatment 
with those who had therapy without any obvious difference in the characteristics or severity of 
ITP and interestingly we found no difference in outcomes between these groups. Most women in 
the treatment group (91%) are treated prophylactically due to platelet count alone and not 
because of symptoms of ITP (Figure S1).  
Strengths   
The strengths are in the UKOSS methodology used to obtain data on a well phenotyped cohort of 
women with severe ITP. All cases were reviewed by the UKOSS team to ensure they met the 
case definition before inclusion and all four authors reviewed the cases individually for 
agreement on inclusion. 
This is the largest cohort study of ITP in pregnancy to date and the first study to report separately 
on the effects of different treatments.  
Limitations 
UKOSS data relies on reporting of monthly cases. Under reporting may occur and to account for 
this a 95% confidence interval has been included with our estimate of incidence. Due to worst 
case reporting bias cases with poor outcomes will likely get a higher local profile, and are more 
likely to be brought to the attention of local UKOSS reporters. We believe that our conclusions 
regarding safety of severe ITP in pregnancy are unlikely to be affected by potential under 
reporting.  
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The non-treated and treated cohorts may not be directly comparable as there maybe unknown 
selective pressure towards more severe cases receiving treatment. Additionally, we do not have 
serial platelet count data from pregnancy or post pregnancy, only the lowest platelet count and 
we are not recommending a change in practise based on this data. 
This data is only for women with platelets <50 x 109/L and those requiring antenatal treatment, 
we cannot comment on neonatal morbidity and mortality risks for patients with platelets above 
50 x109/L who do not receive treatment.  
Interpretation 
Primary PPH currently affects 5 in 100 pregnancies in the UK11 and the risk in our severe ITP 
cohort is approximately ten times higher. This is irrespective of treatment, but statistically more 
likely in women with lower platelet counts at delivery. When considering life-threatening 
haemorrhage (blood loss of ≥2.5 litres, >5 units of blood transfused or treatment for 
coagulopathy after an acute bleed), the rate in Scotland is estimated at 3.7/1000 maternities12 
compared to 3.7/100 cases in this cohort (n=4). There are several possible reasons for this 
frequency. Firstly, delivering by caesarean section (CS) loses more blood on average than 
delivering vaginally. Using an estimated blood loss ≥1000 after CS13 as the definition of PPH, 
the rate would decrease to 24%, which is still five times higher than estimates from the literature. 
Secondly there is criticism of the reported incidence of PPH in the general population; clinicians 
typically underestimate the amount of blood lost at delivery14 and therefore the discrepancy may 
not be as high as reported figures suggest. Thirdly in women with low platelets clinicians may 
subconsciously over-estimate blood loss to ensure closer monitoring in the immediate post-
partum period, leading to over-reporting. Lastly the increase may be a real phenomenon 
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suggesting an abnormality in platelet count or function that predispose ITP mothers to a primary 
PPH.  
Prevention of PPH from uterine atony requires blood vessel vasoconstriction. Platelets have been 
shown to contribute towards vasoconstriction through the release of thromboxane A2. Platelet 
function in severe ITP may be affected by immune complexes formed by platelet antibody. 
Women with Von Willebrand Disease (VWD) have reported PPH rates as high as 29%.15 
Therefore our data suggest that there may be a role of platelet function in prevention of PPH or 
alternatively it may be a combination of over reporting, high CS rate and chance finding in a 
small cohort. This finding should be validated in further work.  
For placement of safe regional anesthesia the minimum platelet count is unknown and most 
anaesthetists will place a regional anesthetic if the platelet count is ≥ 80 x 109/l.3 Only six cases 
had epidurals inserted with platelets <80 x 109/l and no further recommendations regarding a 
minimal platelet count can be made given this small number.  
In order to put our results in the context of the currently available evidence we have reviewed all 
papers describing case-series or cohorts that included at least ten women with ITP in pregnancy. 
Figure S1 shows the diagram of information acquisition. 28 papers reporting outcomes of ITP in 
pregnancy have been summarised in Table S4 and our UKOSS data has been included for 
comparison. 
58% of women had known ITP prior to pregnancy, which is in keeping with estimates from 19 
other studies (median 58%, range 33-87%) and demonstrates that almost half of ITP in women of 
reproductive age will be detected for the first time in pregnancy.  
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Our cohort has a high Caesarean section (CS) rate which matches the median CS rate from the 
literature. The most common reason for unplanned or emergency CS was fetal compromise. This 
may be linked to an earlier recourse to CS if there are concerns for fetal wellbeing, as fetal blood 
sampling is not used due to concerns regarding thrombocytopenia in the baby. Additionally, a 
higher rate of induction of labour (38%) exists in this cohort compared to the English national 
rate of 13.2%16 increasing the likelihood of failed induction of labour resulting in CS.  
Despite better than expected outcomes for this cohort in its entirety, it is possible some women 
are receiving unnecessary treatments which have the potential to cause harm in pregnancy. For 
example, one woman receiving prophylactic steroids had postpartum psychosis, a recognized 
complication of steroids and an obstetric and psychiatric emergency due to the risk of suicide or 
infanticide. The baseline level of post-partum psychosis in the pregnant population is very low at 
1 in 1000 women and incidence of steroid psychosis is not known for the pregnancy population. 
There is insufficient data to attribute this episode of postpartum psychosis directly to 
corticosteroid use as we have not collected data regarding background psychiatric risk. However, 
in women who are well and do not report symptoms of bleeding with severe thrombocytopenia 
in pregnancy caused by ITP, the authors suggest it may be reasonable not to give steroids or 
IVIG treatment in the antenatal period and cover delivery with blood products alone if surgical 
intervention was required. A randomised clinical trial would normally be recommended to 
provide definitive evidence that this is a safe alternative to prophylactic therapy. However a 
definitive randomized trial aiming to quantify the difference in benefits and harm of various 
treatment options is unlikely to be feasible.  Even a multicentre study with more 1,000 
randomised women would not be large enough to exclude a possibility of clinically important 
difference in the risk of serious neonatal complications between treatment groups. A national 
This article is protected by copyright. All rights reserved. 
data registry of severe ITP with internationally agreed individual patient data collections items 
(demographics, covariates, outcomes) seems a logical alternative. 
Conclusion 
The estimated incidence of severe ITP in pregnancy is 1 per 10,000 maternities. Current UK 
management of severe ITP in pregnancy results in an exceptionally low morbidity and mortality 
for the neonate. Mothers with ITP remain at increased risk of severe post-partum haemorrhage 
and should be delivered at units that have the capacity to manage severe PPH effectively. Whilst 
balancing the risks for pregnancy of prophylactic antenatal treatment in asymptomatic women 
against an observed low disease morbidity, we may be over treating asymptomatic patients and 
exposing them to unnecessary side effects of prophylactic platelet treatment. 
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Table 1. Demographics of Women with Severe Thrombocytopaenia in Pregnancy 
Maternal Characteristics (n = 107) No treatment 
(n = 22) 
Antenatal Treatment 
(n = 85) 
P value
Maternal Age, y, a 33 (19-40) 29 (18-42) .102 
Primiparous, n (%) 8 (36) 36 (42) .634 
Singleton pregnancy, n (%) 22 (100) 82 (97) 1.000 
Ethnicity, n (%) †  
White 13 (59) 60 (70.6) .317 
                                                Black 2 (9) 10 (11.9) 
Asian 6 (27) 10 (11.9) 
Other 1 (5) 4 (4.8)
BMI, mean (SD) kg/m2† 26 (7) 25.8 (6) .727 
Smoking, n (%) 1 (5) 16 (19) .184 
Diagnosis of ITP before pregnancy, n (%) 15 (68) 47 (55) .337 
Age at ITP diagnosis, y, a 28 (19 – 32) 23 (2-35) .134 
Lowest platelet count prior to pregnancy 
x 109/la 
19 (2-74) 29.5 (1-119) .178 
amedian (range)  † 2 values missing data. 
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Table 2. Labour and Delivery Management of 107 Women with Severe ITP in the UK 
 No Rx 
(n=22) 
Steroids 
(n = 38) 
IVIG 
(n = 17) 
Steroids + IVIG 
(n = 28) 
Total 
(n = 107) 
Onset of Labour      
Spontaneous 5 (23) 21 (55) 1 (6) 4 (14) 32 (30) 
Induced 9 (41) 8 (21) 10 (59) 13 (46) 41 (38) 
Not Reported 0 0 1 (6) 1 (4) 2 (2) 
Did not labour 8 (36) 9 (24) 5 (29) 10 (36) 32 (30) 
Mode of Delivery      
Caesarean Section, n, % 9 (41) 11 (27) 8 (47) 14 (50) 42 (39) 
Vaginal Delivery, n % 13 (59) 27 (73) 9 (53) 14 (50) 65 (61) 
Fetal Blood Sampling (FBS) in labour, n (%)   
Yes 0 0 0 2 (11) 2 (3) 
No 14 (100) 29 (100) 9 (75) 16 (89) 70 (93) 
Not reported 0 0 3 (25) 0 3 (4) 
Reasons for “no”  FBS   
No indication for FBS 11 (79) 27 (93) 7 (78) 14 (88) 60 (86) 
Concern about low fetal 
platelets 2 (14) 1 (3.5) 1 (11) 1 (6) 5 (7) 
Maternal pyrexia 1 (7) 0 1 (11) 0 2 (3) 
Not known/reported 0 1 (3.5) 0 1 (6) 3 (4) 
Analgesia  for Vaginal Delivery  
Not answered/Not known 1 (8) 0 0 0 2 (3) 
Epidural 2 (15) 3 (11) 3 (33) 2 (14.3) 10 (15) 
None 3 (23) 7 (26) 1 (11) 2 (14.3) 14 (22) 
Opiates 1 (8) 10 (37) 3 (22) 4 (21.4) 18 (28) 
Entonox 6 (46) 7 (26) 2 (22) 6 (43) 21 (32) 
Anaesthesia  for  Caesarean Section 
General 5 (56) 7 (64) 5 (63) 9 (64) 26 (62) 
Spinal 2 (22) 4 (36) 1 (13) 4 (29) 11 (26) 
Epidural 1 (11) 0 2 (25) 1 (7) 4 (10) 
Not known 1 (11) 0 0 0 1 (2) 
Lowest Recorded Platelets 
in Pregnancy x 109/la 31 (6-49) 41 (5-81)* 30 (6-55) 21 (4-54) 32 (4-81) 
Platelets at Delivery      
Number Recorded, n (%) 19 (86) 36 (95) 16 (94) 24 (86) 97 (91) 
Platelet count at delivery, 
109/la 
56  
(14–218) 
77  
(18-206) 
71  
(30–152) 
62  
(12 – 170) 
64  
(12–218) 
a median (range) *One woman meeting UKOSS criteria with ITP confirmed prior to index pregnancy had a lowest 
recorded platelets of 148 x 109/l during pregnancy, steroids were given the  day before and on the day of term vaginal 
delivery. No maternal or neonatal complications of pregnancy or delivery were reported, but this figure has been removed 
from the range and is reported here as an outlier.  
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*2 cases with other treatment reported in text. **In total cohort of 107 there was 1 ITU admission 
following hysterectomy (see text for detail – resistant to therapy, required azathioprine.) 
 
Table 3.  Maternal Outcomes of 105 Women with Severe ITP in the UK 
 No Rx 
(n=22) 
Steroids 
(n = 38) 
IVIG 
(n = 17) 
Steroids + 
IVIG (n = 
28) 
Total 
(n = 105) 
Epidural Haematoma, 
n (%) 0 0 0 0 0 
Perineal Haematoma, 
n (%) 0 0 0 0 0 
CS Wound 
Haematoma, n (%) 0 0 0 0 0 
Estimated Blood Loss, 
median (range), ml 
500 
(150–2000) 
400          
(100 – 2500)
500             
(200 – 2200) 
500          
(100 – 3000) 
500 
(100 – 3000) 
Postpartum 
Haemorrhage, n (%) 10 (45) 17 (45) 9 (53) 18 (64) 54 (51) 
ITU Admission ** 0 0 0 0  0 
Hysterectomy due to 
PPH, n (%)** 0 0 0 0  0 
Psychotic post-partum 
depression, n (%) 0 1 (3) 0 0 1 (1) 
Death, n, (0%) 0 0 0 0 0 
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*2 pregnancies reported as case reports in text (other therapy) **Other 7 cases all discharged without 
therapy for thrombocytopenia but spontaneous recovery of platelet count not recorded on data collection 
form. 
Table 4. Neonatal Outcomes for 108 infants (106 livebirths) of 105 women* with severe maternal ITP  
 No Rx 
(n=22) 
Steroids 
(n=39) 
IVIg 
(n=19) 
Steroids + 
IVIG (n=28) 
Total 
(n = 108) 
Miscarriage, n (%) 1 (4) 0 0 0 1 (1) 
Stillbirth, n (%) 1 (4) 0 0 0 1 (1) 
Birthweight (g)a 3123  
(790 – 
4900) 
3340  
(2360-5020)
3250  
(1860 – 
4135) 
3230  
(2035– 3990) 
3233 (790– 
5020) 
Cord Platelet count x 109/la 174 (59 – 
350) 
212 (76 – 
342) 
245 (79 – 
326) 
193 (88 – 
373) 
193 (59 – 
373) 
Recorded 9 (38) 23 (58) 9 (47) 17 (61) 58 (54) 
Not taken/No result 15 (62) 16 (42) 10 (53) 11 (39) 52 (48) 
Neonatal Thrombocytopenia within First Week, n, (%)   
Yes 6 (27) 7 (18) 2 (11) 8 (29) 20 (19) 
No 9 (41) 21 (54) 13 (68) 12 (43) 58 (54) 
Unknown / Not recorded 7 (32) 11 (28) 4 (21) 8 (29) 30 (28) 
Platelet Nadir   
 <20 x 109/l  0 0 0 0 0 
 20-50 x 109/l 0 0 0 3 (11) 3 (3) 
51 – 100 x 109/l 4 (18) 2 (5) 1 (5) 2 (7) 9 (8) 
150 – 100 x 109/l 2 (9) 5 (13) 1 (5) 3 (11) 11 (10) 
Neonatal sepsis or other cause of 
thrombocytopenia, n, (%) 0 1 (3) 0 1 (4) 2 (2) 
Evidence of spontaneous 
recovery prior to discharge, n 
(%) 
6 (100) 7 (100) 2 (100) 1** 16 (100) 
Admissions to NICU, n (%) 0 2 (5) 1(5) 4 (15) 7 (7) 
Transcranial USS, n (%) 1 (5) 1 (3) 0 0 2 (2) 
Intracranial Haemorrhage, n (%) 0 0 0 0 0 
Death, n (%) 0 0 0 0 0 
